Diabetes, insulin, insulin analogues, and cancer;Diabetes, Insulin, Insulinanaloga und Karzinome

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 18, 2010, Pages 924-929

  Mussig K ^a   Staiger, H ^a   Kantartzis, K ^a   Fritsche, A ^a   Kanz, L ^a   Haring H U ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer; Cancer; Insulin glargine; Mitogenecity

Indexed keywords

INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR;

BASAL CELL CARCINOMA; BREAST CANCER; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HYPERINSULINEMIA; IN VITRO STUDY; LUNG CANCER; MELANOMA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SKIN CANCER;

DIABETES MELLITUS, TYPE 2; EXERCISE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MUTAGENICITY TESTS; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 77951874412     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1253681     Document Type: Review

References (84)

1. IDF Diabetes Atlas, 4th ed. International Diabetes Federation; 2009
2. National Cancer Institute. Surveillance Epidemiology and End Results; 2009
3. Nationale Verzehrsstudie II. Veröffentlichung des Bundesministeriums; 2008
4. Agin A, Jeandidier N, Gasser F et al. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 2007 33 205-212
5. Bähr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997 320 259-265
6. Belfiore A, Frasca F, Pandini G et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009 30 586-623
7. Bernstein L. Identifying population-based approaches to lower breast cancer risk. Oncogene 2008 27 Suppl 2 S3-S8
8. Berthois Y, Katzenellenbogen J A., Katzenellenbogen B S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986 83 2496-2500
9. Berti L, Kellerer M, Bossenmaier B et al. The long acting human insulin analog HOE 901. Horm Metab Res 1998 30 123-129
10. Buse J. Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. Diabetes Care 2000 23 576-578
11. Calle E E., Rodriguez C, Walker-Thurmond K, Thun M J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003 348 1625-1638
12. Ciaraldi T P., Carter L, Seipke G et al. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001 86 5838-5847
13. Colhoun H M. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009 52 1755-1765
14. Coughlin S S., Calle E E. et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004 159 1160-1167
15. Currie C J., Poole C D., Gale E A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 52 1766-1777
16. Dideriksen L H., Jørgensen L N., Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 ASP. Diabetes 1992 41 143A (Abstract)
17. Dombrowski F, Klotz L, Bannasch P, Evert M. Renal carcinogenesis in models of diabetes in rats. Diabetologia 2007 50 2580-2590
18. Draznin B. Mitogenic action of insulin: friend, foe or frenemy? Diabetologia 2010 53 229-233
19. Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007 50 2534-2543
20. El Serag H HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006 4 369-380
21. Friberg E, Orsini N, Mantzoros C S., Wolk A. Diabetes mellitus and risk of endometrial cancer. Diabetologia 2007 50 1365-1374
22. Gammeltoft S, Hansen B F. et al. Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opin Investig Drugs 1999 8 1431-1442
23. Goodwin P J., Ennis M, Pritchard K I. et al. Fasting insulin and outcome in early-stage breast cancer. J Clin Oncol 2002 20 42-51
24. Groves T. Pandemic obesity in Europe. Brit Med J 2006 333 1081
25. Hall G C., Roberts C M., Boulis M et al. Diabetes and the risk of lung cancer. Diabetes Care 2005 28 590-594
26. Hemkens L G., Grouven U, Bender R. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Diabetologia 2009 52 1732-1744
27. Home P D., Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009 52 2499-2506
28. Huxley R, Ansary-Moghaddam A, de Berrington Gonzlez A et al. Type-II diabetes and pancreatic cancer. Br J Cancer 2005 92 2076-2083
29. Jonasson J M., Ljung R, Talback M et al. Insulin glargine use and short-term incidence of malignancies a population-based follow-up study in Sweden. Diabetologia 2009 52 1745-1754
30. Kasper J S., Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009 124 1398-1403
31. Kellerer M, Sesti G, Seffer E et al. Altered pattern of insulin receptor isotypes in skeletal muscle membranes of type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1993 36 628-632
32. Kellerer M, von Eye C H., Muhlhofer A et al. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer 1995 62 501-507
33. Key T J., Appleby P N., Reeves G K. et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003 95 1218-1226
34. Kuerzel G U., Shukla U et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003 19 34-40
35. Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 49 999-1005
36. Lammers R, Gray A, Schlessinger J, Ullrich A. Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 1989 8 1369-1375
37. Larsson S C., Mantzoros C S., Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007 121 856-862 (Pubitemid 47106217)
38. Larsson S C., Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006 49 2819-2823
39. Larsson S C., Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Nat Cancer Inst 2005 97 1679-1687 (Pubitemid 41672234)
40. Leitzmann M F., Ahn J, Albanes D et al. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 2008 19 1267-1276
41. LeRoith D et al. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 2008 116 Suppl 1 S4-S6
42. Liefvendahl E, Arnqvist H J. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 2008 40 369-374
43. Lin S, Sahai A, Chugh S S. et al. High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway. J Biol Chem 2002 277 41725-41735
44. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008 114 38-44
45. Michels K B., Solomon C G. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses Health Study. Diabetes Care 2003 26 1752-1758
46. Milazzo G, Sciacca L, Papa V et al. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 1997 18 19-25
47. Mitri J, Castillo J, Pittas A G. Diabetes and risk of Non-Hodgkins lymphoma: a meta-analysis of observational studies. Diabetes Care 2008 31 2391-2397
48. Moller D E., et al. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 1989 3 1263-1269
49. Mosthaf L, Eriksson J, Hring H U. et al. Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes. Proc Natl Acad Sci USA 1993 90 2633-2635
50. Mosthaf L, Vogt B, Häring H U., Ullrich A. Altered expression of insulin receptor types A and B in the skeletal muscle of non-insulin-dependent diabetes mellitus patients. Proc Natl Acad Sci USA 1991 88 4728-4730
51. Parkin D M., Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 74-108
52. Parkin D M., Whelan S L. Cancer incidence in five continents. 2009 Vol. VIII
53. Pichard C, Plu-Bureau, Neves-E C astro, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 2008 60 19-30
54. Pollak M N., Schernhammer E S., Hankinson S E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004 4 505-518
55. Ratzmann K P. Eine Analyse von alters- und geschlechtsspezifischer Diabetesprävalenz sowie Behandlungsart: die Berlin-Studie. Aktuel Endokrinol Stoffwechsel 1991 12 220-223
56. Reeves G K., Pirie K, Beral V et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study. Brit Med J 2007 335 1134
57. Rohlfing C L., Wiedmeyer H M., Little R R. Defining the relationship between plasma glucose and HbA(1c). Diabetes Care 2002 25 275-278
58. Rollison D E., Giuliano A R., Sellers T A. et al. Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states. Am J Epidemiol 2008 167 447-456
59. Rosenstock J, Fonseca V, McGill J B. et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes. Diabetologia 2009 52 1971-1973
60. Rousseau M C., Parent M E., Pollak M N., Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006 118 2105-2109
61. Saito K, Inoue S, Saito T et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002 51 100-104
62. Saydah S H., Loria C M., Eberhardt M S., Brancati F L. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003 157 1092-1100
63. Schwartz G P., Burke G T., Katsoyannis P G. A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci USA 1987 84 6408-6411
64. Seino S, Bell G I. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 1989 159 312-316
65. Shukla A, Grisouard J, Ehemann V et al. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009 16 429-441
66. Smith P J., Wise L S. et al. Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 1988 263 9402-9408
67. Staiger K, Hennige A M., Staiger H et al. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007 39 65-67
68. Staiger K, Staiger H, Schweitzer M A. et al. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005 48 1898-1905
69. Stammberger I, Bube A, Durchfeld-Meyer B et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002 21 171-179 (Pubitemid 34803492)
70. Stattin P, Bjor O, Ferrari P et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007 30 561-567 (Pubitemid 46354334)
71. Stoll B A. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002 26 747-753
72. Ullrich A, Bell J R., Chen E Y. et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985 313 756-761
73. Velicer C M., Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2007 10 46-51
74. Vigneri P, Frasca F, Sciacca L et al. Diabetes and cancer. Endocr Relat Cancer 2009 16 1103-1123
75. Vinikoor L C., Long M D., Keku T O. et al. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. Cancer Epidemiol Biomarkers Prev 2009 18 1239-1242
76. Wang F, Gupta S, Holly E A. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 2006 15 1458-1463
77. Washio M, Mori M, Khan M et al. Diabetes mellitus and kidney cancer risk: the results of the JACC Study. Int J Urol 2007 14 393-397
78. Waters K M., Henderson B E., Stram D O. et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009 169 937-945
79. Weinstein D, Simon M, Yehezkel E et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009 25 41-49
80. Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause-specific mortality in 900 000 adults. Lancet 2009 373 1083-1096
81. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 1047-1053
82. Wu A H., Yu M C., Tseng C C. et al. Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis 2007 28 1561-1566
83. Yang Y X., Hennessy S, Lewis J D. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005 3 587-594
84. Ye F, Chevrier A M. et al. Insulin-like growth factor I receptors are expressed by the enteroendocrine cell line STC-1. Horm Res 1998 50 183-189